Table 1.
Gene Expression Induction in Cultured Cells Exposed to Plasma of Patients Receiving Placebo and BCG (45 Days Following Intervention)
| Gene Expression | BCG | Placebo | P value |
|---|---|---|---|
| IFITM3, median change ± IQR | 0.12 ± 0.40 | −0.03 ± 0.36 | 0.11 |
| TNF-α, median change ± IQR | 0.08 ± 0.57 | −0.01 ± 0.36 | 0.38 |
| IFNB1, median change ± IQR | 0.19 ± 0.39 | 0.01 ± 0.33 | 0.042 |
| IFNL1, median change ± IQR | 0.05 ± 0.63 | −0.04 ± 0.65 | 0.51 |
| ACE2, median change ± IQR | 0.04 ± 0.57 | −0.21 ± 0.40 | 0.10 |
| AXL, median change ± IQR | −0.01 ± 0.31 | −0.02 ± 0.31 | 0.86 |
| Caspase-8, median change ± IQR | 0.08 ± 0.37 | −0.04 ± 0.28 | 0.10 |
| IL2RA, median change ± IQR | 0.17 ± 0.86 | −0.28 ± 0.80 | 0.054 |
| IL-1β, median change ± IQR | 0.01 ± 0.64 | −0.04 ± 0.35 | 0.41 |
| IL-10, median change ± IQR | −0.01 ± 0.38 | −0.13 ± 0.27 | 0.13 |
| IL-6, median change ± IQR | 0.40 ± 1.15 | −0.19 ± 0.56 | 0.48 |
Abbreviations: IFITM3, interferon-induced transmembrane protein 3; TNF-α, tumor necrosis factor α; IFN, interferon; ACE2, angiotensin-converting enzyme 2; AXL, tyrosine protein kinase receptor UFO; IL, interleukin; IL2RA, interleukin 2 receptor subunit alpha.